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Early increase in blood pressure and diastolic left ventricular
malfunction in patients with glomerulonephritis
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Early increase in blood pressure and diastolic left ventricular malfunc-
tion in patients with glomerulonephritis. In patients with diabetic ne-
phropathy blood pressure increases progressively before the conventional
threshold of normal blood pressure (140/90 mm Hg) is transgressed. In
patients with glomerulonephritis, no information on this point is available.
To clarify this issue we sequentially examined 20 untreated patients with
biopsy-proven primary chronic glomerulonephritis (GN) who had casual
blood pressure below 140/90mm Hg and normal GFR by inulin clearance.
Patients were compared with normotensive healthy controls who were
matched for BMI, gender and age. We measured ambulatory 24-hour
blood pressure (SpaceLab system), echocardiography (ASE criteria, Acu-
son 128 XP 10), C1 and CPAFI, urinary Na excretion, PRA and insulin
concentration. In patients with GN, the median 24 hour (P < 0.0005),
daytime (P < 0.001) and nocturnal sleeping time (P < 0.0001) MAP values
were significantly higher than in matched controls (daytime, mean 97 mm
Hg, 85 to 106 GN vs. 89 controls range 82 to 102; nocturnal sleeping time,
mean 80.3 mm Hg, 71 to 89.5 GN vs. 73 controls, range 63 to 84).
Echocardiographic examination showed significantly greater posterior
wall thickness (P < 0.01) and ventricular septal thickness (P < 0.003). In
addition the early diastolic to late diastolic (E/A) ratio of mitral valve peak
inflow velocity was significantly (P < 0.0008) lower in patients. The data
point to left ventricular wall thickening accompanied by LV diastolic
malfunction. The study documents elevated ambulatory blood pressure in
patients with primary chronic glomerulonephritis despite normal body
weight and normal GFR. This is associated with evidence of target organ
damage in the heart. The findings suggest that in patients with glomeru-
lonephritis blood pressure increases initially within the normotensive
range. This observation in conjunction with evidence of early target organ
changes provides an argument for early antihypertensive intervention, but
controlled trials to test efficacy and safety of this proposal are necessary.
Several investigators were able to show that patients with type
I diabetes who had microalbuminuria, that is, incipient nephrop-
athy, had higher blood pressures than diabetics without mi-
croalbuminuria [1, 2]. This was noted even though casual blood
pressure still remained within the range of normotension by the
WHO definition.
Similar observations in patients with incipient renal damage
from diseases other than diabetic nephropathy are sparse. In one
study, a reversible increase in blood pressure was noted when
children had an episode of nephrotic syndrome secondary to
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minimal change glomerulonephritis, that is, normal glomeruli by
light microscopy [3]. During relapse blood pressure was consis-
tently above the 95th percentile for age and returned towards the
normotensive range after remission. Furthermore, some studies
documented the presence of arteriolar hyalinosis in normotensive
patients with glomerulonephritis, pointing to abnormal intrarenal
hemodynamics early on [4].
When a normotensive individual develops glomerulonephritis it
is obvious that his or her blood pressure must increase within the
range of normotension defined by WHO [5] or Joint National
Committee [6] before the blood pressure reaches the frankly
hypertensive range. Longitudinal studies to document such a rise
in blood pressure would be desirable, but are difficult to perform,
because patients are usually not monitored before glomerulone-
phritis has been diagnosed.
To circumvent this difficulty we chose to perform a case control
study. We examined patients with biopsy-confirmed IgA glomer-
ulonephritis as a paradigm of primary chronic glomerulonephritis
with a casual blood pressure within the range of normotension by
the WHO definition and a normal renal function by inulin
clearance. Such patients were compared with controls matched
for body mass index (BMI), gender and age. We tested the
working hypothesis that circadian blood pressure and cardiac wall
thickness are higher in patients with glomerulonephritis than in
their matched controls.
Methods
Selection of patients and controls
The 20 patients in this study were recruited consecutively from
the renal outpatient clinic of the University of Heidelberg.
Inclusion into the study was based on the following criteria: (i)
biopsy proven diagnosis of IgA glomerulonephritis; (ii) normo-
tension, that is, <140/90 mm Hg of casual blood pressure in the
outpatient clinic using sphygomanometric determination accord-
ing to the recommendations of the German League against High
Blood Pressure; and (iii) no use of an antihypertensive medica-
tion. Exclusion criteria were: (i) elevated serum creatinine (>1.1
mg/dl); (ii) age above 45 years; (iii) BMI  28 kg/rn2; (iv) presence
of extrarenal disease; (v) proteinuria  3.5 g/24 hr; (vi) hormonal
contraception. All consecutive 29 patients hiopsied from January
1, 1991 to December 31, 1994 with the diagnosis of IgA glomer-
ulonephritis who met the above criteria were approached; 20
patients agreed to participate in the study after informed consent
was obtained. The study protocol had been approved by the ethics
committee of the Faculty of Medicine, Heidelberg, Germany.
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Twenty control subjects, matched for BMI, gender and age, were
healthy normotensive individuals as confirmed by history and
physical examination. They were recruited from the collaborators
of the renal unit or were relatives of dialysis patients.
Blood pressure measurements
Casual blood pressure was assessed with a mercury sphygmo-
manometer before fitting to an ambulatory monitor. Ambulatory
blood pressure (BP) was measured during a 24 hour period with
a programmable blood pressure monitor (ABD monitor type
90207; SpaceLabs Inc., Redmond, WA, USA). The time interval
of measurements was 20 minutes between 6:00 and 22:00 hours,
and 30 minutes between 22:00 and 6:00 hours. The daytime period
was defined as the interval from 10:00 to 20:00 hours and night
time as the interval from midnight to 6:00 hours. Since some
studies [7] have shown that in most subjects blood pressure
changes rapidly and considerably when subjects fall asleep and
wake up, individuals were asked to record their sleeping times.
The period selected for night time analysis was well within the
period of documented sleep.
Echocardiographic study
After the BP monitoring period, patients and control subjects
had an echocardiographic examination by one investigator (K.S.)
who was unaware of the renal status. Echocardiographic studies
were performed in left lateral supine position using an Acuson 128
X P 10 System (Mountain View, CA, USA) interfaced with 3 or 5
MHz transducers. From real time directed M-mode echocardiog-
raphy, left ventricular internal diameter (LVID), ventricular
septal thickness (VS), and posterior wall thickness (PW) were
measured in the parasternal long and short axis cuts at end-
diastole (D) and end-systole (5). Aortic diameter (Ao) was
measured in the diastole, and left atrial diameter (LA) in the
systole. Left ventricular pre-ejection period (PEP), ejection time
(ET) and heart rate were measured from opening and closing
movements of the aortic valve leaflets and the onset of the R-wave
in the ECG. M-mode measurements were made according to the
recommendations of the American Society of Echocardiography
[81. They were repeated in three to five consecutive beats and
averaged.
From M-mode data we calculated three indices of the LV
systolic function, that is: (i) left ventricular fractional shortening
(FS) as
FS = (LVIDD- LVIDS)/LWDD
and (ii) rate-corrected mean velocity of circumferential fiber
shortening (mVcf) as
mVcf = (LVIDD — LVIDS)/(LVLDD X LVETc)
Left ventricular ejection time (LVET) was corrected for a heart
rate of 60 beats/mm by dividing it by the square root of the RR
interval.
Finally, (iii) the systolic ratio is PEP/LVET. The left ventricular
mass (LVM) was calculated using the formula of Devereux et al
[9] as
LVM = 0,832 x {(VSD + LVIDD + PWD)3 — LVID3} + 0.6
LVM was then normalized for body surface area (LVMI).
From the apical window pulsed Doppler interrogation of the
aortic and mitral valves was performed just distal to the respective
valve ring. Three to five beats were analyzed and averaged. We
measured peak velocity (PkV) and mean acceleration (Acc) at the
aortic valve and the early diastolic (E) and late diastolic (A)
transmitral peak inflow velocities as well as the ratio EtA.
Measurements of renal hemodynamics
Inulin (C10) and PAH (CPAH) clearances were used to deter-
mine glomerular filtration rate (GFR) and effective renal plasma
flow (RPF), respectively, as described previously [10]. Clearances
were measured after an overnight fast at a standardized time (8:00
hours) in the morning. The patients or the control subjects rested
in a quiet room in supine position. First, blood was taken for
routine chemistry and for plasma renin activity (PRA) and plasma
insulin measurements. Subsequently, a bolus of 1500 mg inulin/m2
of body surface (mutest, Laevosan-Gesellschaft, Linz, Austria)
and 500 mg of paraaminohippurate/m2 (Nephrotest, Biol. Ar-
beitsgemeinschaft, Lich, Germany) was administered. This was
immediately followed by a continuous infusion of 10 mglm2/min of
both substances for 270 minutes. Beginning 90 minutes after the
bolus injection, blood samples were taken at 10 minute intervals.
Blood pressure was measured during the entire period using
Dinamap (Criticon Inc., Tampa, FL, USA). Inulin was measured
using a two step enzymatic assay [111 and PAH using colorimetiy
[121.
Ancillary measurements
Plasma insulin was measured using an ELISA/1-Step-Sand-
wich-Assay (Enzymimmunsystem ES 300; Boehringer Mann-
heim). PRA was measured according to Haber et al [13], and PTH
using the Nichols assay. Urinary protein was measured using the
Biuret method. Routine serum and urine parameters were as-
sessed using an autoanalyzer Hitachi 705 (Boehringer Mann-
heim).
Evaluation of renal biopsies
The presence and severity of intrarenal arterial sclerosis and
arteriolar hyalinosis was evaluated on serial biopsy sections using
a score system from zero to three. Arterial sclerosis was defined
as: 0 = absent; 1+ = mild segmental intimal thickening and
fibrosis; 2+ = circumferential intimal thickening and fibrosia; 3+
= severe intimal thickening with pronounced narrowing of the
lumen. Arteriolar hyalinosis was defined as: 0 = absent; 1 + =
segmental subendothalial hyaline deposits; 2+ = circumferential
subendothelial hyaline deposits; 3+ = circumferential subendo-
thelial hyaline deposits with severe narrowing of the lumina.
Statistics
Data are reported as median and range. Comparisons between
patients and matched controls were made using Wilcoxon's test
for paired samples. Univariate analysis and multivariate analysis
were calculated using the Stat-view 4.1. program.
To avoid Bonferroni problems from repetitive testing, only
three parameters were preselected for primary hypothesis testing
(24 hour MAP, VS, PW) for which a P < 0.05 was accepted.
Significance testing for the other parameters was considered as a
posthoc analysis for the generation of the hypothesis.
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Glomerulonephritis 31 10/10 22.1 0.94 1.01 156 0.76 7.55(N = 20) (21—45) (18.7—28.1) (0.69—1.32) (0.04—3.40) (77—278) (0.15—4.95) (2.32—14.2)
Matched controls 31 10/10 22.0 0.89 0.05a 152 0.65 6.21
(N = 20) (25—44) (18.3—31.6) (0.70—1.15) (0.04—0.25) (66—231) (0.15—1.85) (2.68—10.1)
Range of values is in the parentheses.
Abbreviations are: BMI, body mass index; UVprotej, urinary protein excretion; UVNa, urinary sodium excretion; PRA, plasma renin activity; Insulin,
fasting insulin.
Significant paired difference
Table 2. Blood pressure (mm Hg)
Results
Baseline data
Table I illustrates that patients with IgA glomerulonephritis
and controls were reasonably matched with respect to BMI,
gender and age. By definition all patients had casual systolic blood
pressures (and diastolic blood pressures; data not shown) within
the range of normotension according to WHO [5], that is,
<140/90 mm Hg. Normal blood pressure according to JNC
criteria [6], that is, <130/85 mm Hg, was found in 16 of 20
patients. All patients had normal serum creatinine concentration
and non-nephrotic proteinuria.
All patients had near normal 1,84 iPTH levels (median 4.9
pmol/liter, range 0.7 to 7.9; normal < 6 pmol/liter).
Evaluation of preglomerular vessels in renal biopsies
The presence of arterial sclerosis and arteriolar hyalinosis in the
renal biopsies was evaluated by one examiner (R.W.) who was
unaware of the clinical findings. Arteries were not present on
serial sections of 5 of 20 biopsies; no sclerosis was found in 8 of 15
and grade I arterial sclerosis in 7 of 15 specimens. Arteriolar
hyalinosis was absent in 5 of 20 biopsies, grade 1 hyalinosis in 14
of 20 and grade 2 in 1 of 20 of the biopsies.
Blood pressure measurements
Average 24-hour blood pressure was significantly higher in
patients compared to their matched controls (Table 2 and Fig. 1).
There was no significant difference of heart rates. The elevation
was quantitatively similar for the periods when the patients were
awake or asleep. This was similarly true for systolic BP and
diastolic BP. There was a significant difference of 24 hour MAP
between male (95 mm Hg; range 9lto 100 mm Hg) and female
patients (88.5 mm Hg; range 82 to 96; P < 0.005) as well as male
(89 mm Hg; range 81 to 96 mm Hg) and female (83.5 mm Hg; 78
to 89 mm Hg) controls (P < 0.05). By multivariate analysis MAP
in patients was not related to proteinuria, age or PRA; a modest
relation was found to Na excretion (r =0.55; P < 0.004), BMI (r
0.67; P < 0.03) and fasting insulin level (r = 0.63; P < 0.02).
Renal hemodynamics
All patients with IgA glomerulonephritis had C well within
the normal range (in our laboratory 121 11 ml/min/1.73 m2).
There was no significant difference of baseline C1, CPA11 or
renovascular resistance (RVR) between patients with glomerulo-
nephritis and healthy controls (Table 3).
Echocardiographic data
Cavity lumina (that is, LVIDD and LA) as well as aortic
diameter were not significantly different between patients with
IgA glomerulonphritis and their matched controls (Table 4, Table
5 and Fig. 2). In contrast, a significant difference of ventricular
septal and posterior wall thickness was noted. LVMI tended to be
higher in patients (78.6 g/m2; range 48.4 to 133 g/m2) than in
matched controls (70.6 gIm2; range 57.8 to 94.3 g/m2), but the
difference did not reach statistical significance. The relative wall
thickness, that is, the LVIDD (VS + PW) ratio, was significantly
lower in patients compared to matched controls (P < 0.002). All
indices of systolic LV function were within normal limits and did
not show significant differences between patients and matched
controls. There was, however, a strikingly significant difference in
the E/A ratio indicating a disturbed diastolic LV function. With
the exception of one pair there was no overlap of the E/A ratio
between matched pairs.
By multivariate analysis, the ventricular septum (r 0.56; P <
0.03) and posterior wall thickness (r 0.7; P < 0,05) were
moderately correlated with BMI in renal patients.
Casual blood pressure 24 hr Blood pressure Daytime blood pressure Nighttime blood pressure
Systolic Diastolic MAP Systolic Diastolic MAP Systolic Diastolic MAP Systolic Diastolic MAP
(GN vs. controls)
a Paired differences
Glomerulonephritis 125 80 95 124.5 76.5 93 129 82 97 111 64.8 80.2(N = 20) (110—140) (70—90) (83—105) (107—135) (69—84) (82—100) (107—141) (73—88) (85—106) (96.5—128.5) (56.5—72) (71—89.5)
Matched controls 120 72.5 90 114.5 70.5 84.5 119 75 88.5 103 58 73
(N = 20) (105-430) (60—85) (75—100) (106—135) (62—79) (78—96) (108—144) (66—87) (82—102) (91—117) (48—70) (63—84)
pa 0.04 0.04 0.02 0.007 0.0006 0.0005 0.012 0.003 0.001 0.003 0.001 0.0001
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Table 3. Renal hemodynamics
Discussion
The present study provides controlled quantitative information
on the circadian blood pressure profile in patients with biopsy-
confirmed IgA glomerulonephritis, normal GFR, non-nephrotic
proteinuria and normotension by the WHO definition [5] accord-
ing to casual blood pressure measurements. Such patients have
daytime and night time blood pressure values that are significantly
higher than those of controls matched for BMI, gender and age.
This finding indicates that early on in the natural history of
glomerulonephritis, the circadian blood pressure is clearly inap-
propriately high, that is, it is shifted to the right with respect to the
blood pressure distribution in the normal population. This is the
more remarkable since most casual BP values were normal even
according to the rigorous Joint National Committee [6] criteria.
The argument that such blood pressure values are inappropriate is
further reinforced by the observation of early target organ dam-
age: measurements of LV wall thickness showed significantly
higher values in patients with IgA glomerulonephritis, although
they were still within the normal range [14]. An increase in wall
thickness despite no significant change in LV mass index presum-
ably reflects the fact that the relationship between LV internal
diameters and volume is changed (so called "ventricular remod-
eling"). This is suggested by the finding of an increased relative
wall thickness in our patients. While systolic LV function was
completely normal, striking evidence of abnormal E/A ratios was
noted, pointing to early diastolic LV malfunction. Early diastolic
malfunction is reminiscent of what has been noted in patients with
genetic predisposition to primary hypertension [15]. Whether LV
Baseline
C1. RVR
mi/mini mi/mini mm Hg/iiter/
1. 73mg 1.73 mm/i. 73 m2
Glomerulonephritis 113 (89.5—140) 639 (472—779) 133 (103—207)(N = 20)
Matched controls 120 (102—177) 661 (451—911) 132 (84.5—202)(N = 20)
Abbreviations are: C1, inulin clearance; CPAH, PAH clearance; RVR,
renovascular resistance.
diastolic malfunction in our patients is related to hypertrophy
and/or cardiac fibrosis [16, 17] is unknown and only histological
studies will resolve this issue in the future. As to the cause of LV
wall thickening, several possibilities can be entertained. It may not
all be caused by high blood pressure and conceivably volume
factors or sympathetic overactivity might play a role, but we
assume that high blood pressure is at least a permissive factor.
Our data are also in agreement with preliminary observations of
cardiac changes in normotensive patients with primary glomeru-
lonephritis [18].
The observed differences are small, but we did not expect
otherwise, since we studied normotensive individuals with incipi-
ent renal abnormalities. Nevertheless, the strength of our argu-
ment is reinforced by the fact that different and independent
approaches led to the same conclusion, that is, measurements of
blood pressure, of septal and posterior wall thickness, and evalu-
ation of diastolic LV function.
When designing the study we considered several biostatistical
artifacts. We recruited all consecutive patients with IgA glomer-
ulonephritis who met the entry criteria to avoid selection bias.
Controls were from the same geographical area and reasonably
matched for factors known to influence blood pressure, such as
body mass index, gender and age. All females were off hormonal
contraception. We also monitored several parameters which
influence blood pressure, for example, BMI, PRA, fasting insulin
concentrations and sodium intake (as assessed from 24-hour
urinary sodium excretion).
The data summarized in Table 1 indicate that with respect to
BMI, serum creatinine, sodium excretion, PRA and fasting insu-
lin, no significant differences existed between the two study
groups. We are aware that circulating PRA is not a good index of
the activity of the renal renin system, as recently shown in a study
by quantitating glomerular renin mRNA with RT-PCR [19].
Consequently, normal circulating PRA does not imply that high
blood pressure is unrelated to the renin system.
All our patients with glomerulonephritis had normal GFR by
inulin clearance. We emphasize, however, that a decrease in
filtration surface area does not necessarily translate into a de-
crease in whole kidney GFR because of glomerular adaptive
mechanisms [20].
The present study was not designed to examine the mechanisms
involved in raising blood pressure. Such mechanisms may include
abnormal renal sodium handling [21], inappropriate activity of the
intrarenal [22] and extrarenal [23] renin system as well as in-
creased responsiveness to angiotensin II. Inappropriate activity of
other pressor or depressor systems, particularly on the renovas-













Fig. 1. Averages of the MAP values (mean arterial blood pressure) of
patients with glomendonephritms and control subjects. Bar denotes median
value.
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Table 4. Echocardiographic and ancillary data (I)




Glomerulonephritis 45 (38—56) 31(26.5—39) 28 (23—32.5) 9.00 (7—12) 9.00 (6.5—11.5) 78.6 (48.4—133) 2.56 (2.05—3.19)
(N= 19)
Matched controls 47.5 (42—55) 31.5 (27.5—37) 29 (25—33) 8.00 (7—9.5) 8.00 (7—10) 70.6 (57.8—94.3) 3.0 (2.21—3.71)(N = 19)P 0.06 0.68 0.33 0.001 0.004 0.82 0.002
Abbreviations are: LVEDD, left ventricle end-diastolic diameter; LA, left atrial diameter; Ao, aortic root diameter; VS, ventricular septum diameter;
PW, posterior wall thickness; LVMI, left ventricular mass index; relative wall thickness (LVEDD/VS + PW) ratio.
Difference is GN vs. matched controls (paired difference; 1 pair could not be evaluated for technical reasons)












Glomerulonephritis 0.36 (0.31—0.42) 1.13 (1.03—1.39) 0.31 (0.26—0.34) 1.03 (0.90—1.30) 19.2 (16.9—20.9) 1.77 (1.03—2.42)(N = 19)
Matched controls 0.35 (0.31—0.40) 1.12 (0.97—1.36) 0.30 (0.24—0.34) 1.10 (0.85—1.40) 19.2 (17.5—21.9) 2.29 (1.61—3.19)(N = 19)
pa 0.88 0.59 0.59 0.24 0.23 0.0003
Abbreviations are: SF, shortening fraction; mVcf, mean velocity of circumferential shortening; PEP/LVET, ratio pre-ejection period/left ventricle
ejection time; mAcc, mean acceleration; EtA ratio, mitral inflow velocity (early diastole/atrial contraction).
a Difference is GN versus matched controls (paired difference; I pair could not be evaluated for technical reasons)
lipin, has been postulated [271. Our protocol did not provide
measurements addressing these issues, but it is of note that
despite normotension, the above patients had marked abnormal-
ities of intrarenal arterioles. This observation is inline with
previous reports of Feiner et a! [4] and is consistent with abnormal
intrarenal pressures.
The finding of increased LV wall thickness is not only interest-
ing as evidence of blood pressure-dependent target organ dam-
age. It may also be relevant for patient survival, since left
______
ventricular mass is related to the risk of cardiac death in patients
with essential hypertension [281 as well as in patients with renal
failure [29, 30].
______
Casual blood pressure emerges from the above observations as
seriously underestimating the circadian blood pressure load to
target organs in patients with glomerulonephritis and normal
glomerular filtration. This observation may have practical impli-
cations in that it provides a rationale for early antihypertensive
intervention. This would be analogous to what is considered state
of the art in diabetic patients with microalbuminuria [31, 32]. The
finding of intrarenal vascular abnormalities in normotensive pa-
tients with IgA glomerulonephritis may provide a further ratio-
nale for antihypertensive intervention. The benefit from, and
_______________
safety of, such early antihypertensive treatment must be docu-
Controls mented, however, by controlled trials, before this recommenda-
tion can be generally accepted.
Reprint requests to Professor Dr. Dr.h.c. E. Ritz, Department of Internal
Medicine, Beigheirner So-a/ic 58, D-6911 75 Heidelberg, Germany.
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